These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 29269868)

  • 1. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
    Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
    Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The transcription factor FOXM1 regulates the balance between proliferation and aberrant differentiation in head and neck squamous cell carcinoma.
    Roh V; Hiou-Feige A; Misetic V; Rivals JP; Sponarova J; Teh MT; Ferreira Lopes S; Truan Z; Mermod M; Monnier Y; Hess J; Tolstonog GV; Simon C
    J Pathol; 2020 Jan; 250(1):107-119. PubMed ID: 31465124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation.
    Zhou G; Wang J; Zhao M; Xie TX; Tanaka N; Sano D; Patel AA; Ward AM; Sandulache VC; Jasser SA; Skinner HD; Fitzgerald AL; Osman AA; Wei Y; Xia X; Songyang Z; Mills GB; Hung MC; Caulin C; Liang J; Myers JN
    Mol Cell; 2014 Jun; 54(6):960-974. PubMed ID: 24857548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells.
    Vaughan CA; Singh S; Grossman SR; Windle B; Deb SP; Deb S
    Mol Oncol; 2017 Jun; 11(6):696-711. PubMed ID: 28423230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma.
    Ganci F; Pulito C; Valsoni S; Sacconi A; Turco C; Vahabi M; Manciocco V; Mazza EMC; Meens J; Karamboulas C; Nichols AC; Covello R; Pellini R; Spriano G; Sanguineti G; Muti P; Bicciato S; Ailles L; Strano S; Fontemaggi G; Blandino G
    Clin Cancer Res; 2020 Jun; 26(12):2956-2971. PubMed ID: 31969334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells.
    Zhang X; Cheng L; Minn K; Madan R; Godwin AK; Shridhar V; Chien J
    Oncotarget; 2014 Nov; 5(22):11365-80. PubMed ID: 25426548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant p53 in head and neck squamous cell carcinoma: Molecular mechanism of gain‑of‑function and targeting therapy (Review).
    Li M; Sun D; Song N; Chen X; Zhang X; Zheng W; Yu Y; Han C
    Oncol Rep; 2023 Sep; 50(3):. PubMed ID: 37449494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retinoids induce antagonism between FOXO3A and FOXM1 transcription factors in human oral squamous cell carcinoma (OSCC) cells.
    Osei-Sarfo K; Gudas LJ
    PLoS One; 2019; 14(4):e0215234. PubMed ID: 30978209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms.
    Lindemann A; Patel AA; Silver NL; Tang L; Liu Z; Wang L; Tanaka N; Rao X; Takahashi H; Maduka NK; Zhao M; Chen TC; Liu W; Gao M; Wang J; Frank SJ; Hittelman WN; Mills GB; Myers JN; Osman AA
    Clin Cancer Res; 2019 Sep; 25(18):5650-5662. PubMed ID: 31308060
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    García-Carracedo D; Cai Y; Qiu W; Saeki K; Friedman RA; Lee A; Li Y; Goldberg EM; Stratikopoulos EE; Parsons R; Lu C; Efstratiadis A; Philipone EM; Yoon AJ; Su GH
    Mol Cancer Res; 2020 Jun; 18(6):822-834. PubMed ID: 32152233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-324-5p-CUEDC2 Axis Mediates Gain-of-Function Mutant p53-Driven Cancer Stemness.
    Ghatak D; Datta A; Roychowdhury T; Chattopadhyay S; Roychoudhury S
    Mol Cancer Res; 2021 Oct; 19(10):1635-1650. PubMed ID: 34257080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo.
    Xiong S; Chachad D; Zhang Y; Gencel-Augusto J; Sirito M; Pant V; Yang P; Sun C; Chau G; Qi Y; Su X; Whitley EM; El-Naggar AK; Lozano G
    Cancer Res; 2022 May; 82(10):1926-1936. PubMed ID: 35320355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis.
    Liu H; Song Y; Qiu H; Liu Y; Luo K; Yi Y; Jiang G; Lu M; Zhang Z; Yin J; Zeng S; Chen X; Deng M; Jia X; Gu Y; Chen D; Zheng G; He Z
    Cell Death Differ; 2020 Mar; 27(3):966-983. PubMed ID: 31296961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of TP63 Promotes the Metastasis of Head and Neck Squamous Cell Carcinoma by Activating MAPK and STAT3 Signaling.
    Lakshmanachetty S; Balaiya V; High WA; Koster MI
    Mol Cancer Res; 2019 Jun; 17(6):1279-1293. PubMed ID: 30910837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma.
    Jin S; Yang X; Li J; Yang W; Ma H; Zhang Z
    Mol Cancer; 2019 Mar; 18(1):38. PubMed ID: 30857539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxiredoxin II promotes hepatic tumorigenesis through cooperation with Ras/Forkhead box M1 signaling pathway.
    Park YH; Kim SU; Kwon TH; Kim JM; Song IS; Shin HJ; Lee BK; Bang DH; Lee SJ; Lee DS; Chang KT; Kim BY; Yu DY
    Oncogene; 2016 Jul; 35(27):3503-13. PubMed ID: 26500057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma.
    Jiang L; Wu X; Wang P; Wen T; Yu C; Wei L; Chen H
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):971-81. PubMed ID: 25391371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
    Yeudall WA; Vaughan CA; Miyazaki H; Ramamoorthy M; Choi MY; Chapman CG; Wang H; Black E; Bulysheva AA; Deb SP; Windle B; Deb S
    Carcinogenesis; 2012 Feb; 33(2):442-51. PubMed ID: 22114072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion.
    Bayraktar R; Ivan C; Bayraktar E; Kanlikilicer P; Kabil NN; Kahraman N; Mokhlis HA; Karakas D; Rodriguez-Aguayo C; Arslan A; Sheng J; Wong S; Lopez-Berestein G; Calin GA; Ozpolat B
    Clin Cancer Res; 2018 Sep; 24(17):4225-4241. PubMed ID: 29748184
    [No Abstract]   [Full Text] [Related]  

  • 20. STAT3:FOXM1 and MCT1 drive uterine cervix carcinoma fitness to a lactate-rich microenvironment.
    Silva LS; Goncalves LG; Silva F; Domingues G; Maximo V; Ferreira J; Lam EW; Dias S; Felix A; Serpa J
    Tumour Biol; 2016 Apr; 37(4):5385-95. PubMed ID: 26563366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.